<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wei X</submitter><funding>Jilin Provincial Natural Science Foundation</funding><funding>Department of Science and Technology of Jilin Province</funding><pagination>28032</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11564816</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Renal fibrosis is a common outcome of chronic kidney diseases and glycolysis drives the development of renal fibrosis in damaged kidneys. Ulinastatin (UTI) is a broad-spectrum protease inhibitor with anti-inflammatory and antioxidant properties with anti-fibrosis effects. In this study, we aimed to verify whether UTI could exert anti-renal fibrosis effects by inhibiting glycolysis and explored the potential mechanisms. Renal fibrosis was induced in mice via unilateral ureteral obstruction (UUO). Transforming growth factor-β1 stimulates human kidney proximal tubular epithelial cells to undergo fibrotic changes. Histopathological staining was used to observe the pathological changes in the kidneys. The levels of fibrosis biomarkers, glycolytic enzymes, and key signaling molecules were determ</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Ulinastatin attenuates renal fibrosis by regulating AMPK/HIF-1α signaling pathway-mediated glycolysis.</pubmed_title><pmcid>PMC11564816</pmcid><funding_grant_id>YDZJ202301ZYTS012</funding_grant_id><funding_grant_id>YDZJ202401170ZYTS</funding_grant_id><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Fan Z</pubmed_authors><pubmed_authors>Long M</pubmed_authors><pubmed_authors>Wei X</pubmed_authors><pubmed_authors>Du Y</pubmed_authors><pubmed_authors>Hou Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ulinastatin attenuates renal fibrosis by regulating AMPK/HIF-1α signaling pathway-mediated glycolysis.</name><description>Renal fibrosis is a common outcome of chronic kidney diseases and glycolysis drives the development of renal fibrosis in damaged kidneys. Ulinastatin (UTI) is a broad-spectrum protease inhibitor with anti-inflammatory and antioxidant properties with anti-fibrosis effects. In this study, we aimed to verify whether UTI could exert anti-renal fibrosis effects by inhibiting glycolysis and explored the potential mechanisms. Renal fibrosis was induced in mice via unilateral ureteral obstruction (UUO). Transforming growth factor-β1 stimulates human kidney proximal tubular epithelial cells to undergo fibrotic changes. Histopathological staining was used to observe the pathological changes in the kidneys. The levels of fibrosis biomarkers, glycolytic enzymes, and key signaling molecules were determ</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2026-06-02T03:36:55.611Z</modification><creation>2025-04-05T18:41:20.3Z</creation></dates><accession>S-EPMC11564816</accession><cross_references><pubmed>39543285</pubmed><doi>10.1038/s41598-024-78092-0</doi></cross_references></HashMap>